As PSMB2 is a robust prognostic factor, in this study, PSMB2 expression and clinical information were used to generate a figure to predict glioma patient OS at 1, 2, and 3 years, which is helpful for screening real-threat patients and determining optimal treatment plans for real-threat glioma patients. Here, PSMB2 is linked to central nervous system cancer.